PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 87 filers reported holding PMV PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,413,122 | +55.6% | 2,347,414 | +58.6% | 0.03% | +62.5% |
| Q2 2023 | $9,263,968 | +40.6% | 1,479,867 | +7.1% | 0.02% | +6.7% |
| Q1 2023 | $6,588,940 | -45.3% | 1,381,329 | -0.3% | 0.02% | -68.1% |
| Q4 2022 | $12,051,823 | -33.2% | 1,385,267 | -8.7% | 0.05% | -19.0% |
| Q3 2022 | $18,055,000 | -16.6% | 1,517,246 | -0.2% | 0.06% | 0.0% |
| Q2 2022 | $21,659,000 | -35.0% | 1,519,935 | -5.0% | 0.06% | -13.4% |
| Q1 2022 | $33,303,000 | -9.9% | 1,599,553 | 0.0% | 0.07% | -1.5% |
| Q4 2021 | $36,949,000 | -12.7% | 1,599,553 | +12.7% | 0.07% | -4.2% |
| Q3 2021 | $42,303,000 | +9.8% | 1,419,553 | +25.9% | 0.07% | +24.6% |
| Q2 2021 | $38,513,000 | +3.7% | 1,127,418 | -0.2% | 0.06% | +3.6% |
| Q1 2021 | $37,155,000 | -46.4% | 1,129,681 | +0.2% | 0.06% | -51.3% |
| Q4 2020 | $69,331,000 | +311.1% | 1,127,151 | +137.3% | 0.11% | +264.5% |
| Q3 2020 | $16,863,000 | – | 475,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |